Currently, the FDA-approved qPCR test to identify Epidermal Growth Factor Receptor (EGFR) mutations, is a diagnostic test that replaces the tissue biopsy in patients with metastatic non-small cell lung cancer who would be eligible for treatment with EGFR-targeted therapy (erlotinib) (11). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.